IRVINE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit
against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX). Investors who purchased or otherwise acquired Akari
shares from March 30, 2017 through May 11, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by the
July 11, 2017 lead plaintiff motion deadline.
If you purchased Akari shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von
Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney.
You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed
to disclose that: its Chief Executive Officer, Dr. Gur Roshwalb, and possibly other executives, were involved in publishing
false information about the Company, including the Phase 2 PNH trial of Coversin; that Akari lacked sufficient checks and
protections to prevent such behavior; and that as a result of the above, the Company’s statements about its business, operations,
and prospects were false and misleading and/or lacked a reasonable basis. On May 11, 2017, Akari announced that Dr. Roshwalb has
been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in
a materially inaccurate research report that was released and subsequently withdrawn on April 26, 2017 by Edison Investment
Research Ltd. When this information reached the public, Akari’s stock price lowered materially, which harmed investors according to
the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please
contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via
e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com
